Showing 41-50 of 56 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Project Tuyinza | The Sonia Nabeta Foundation | Vivian Nabeta | Mission | 01-April-2026 to 31-March-2029 | $643,550.00 |
| Quality, Equity & Outcomes Program | The Sonia Nabeta Foundation | Vivian Nabeta | Mission | 01-September-2026 to 31-August-2028 | $1,400,000.00 |
| The Development of 3-β-hydroxybutyrate binding protein based electrochemical micro-sensor and its application for CKM system | The University of North Carolina at Chapel Hill | Koji Sode | Improving Lives | 01-October-2022 to 30-September-2026 | $799,999.96 |
| Targeting type 1 Diabetes through Polyamines with DFMO | Trustees of Indiana University | Emily Sims | Cures | 01-October-2022 to 30-September-2027 | $3,693,701.00 |
| Reducing the Burden of Type 1 Diabetes Using Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances | University of California, San Diego | Schafer Boeder | Improving Lives | 01-July-2022 to 30-June-2027 | $749,956.58 |
| Microneedle Sensor for Simultaneous Continuous Monitoring of Ketone and Glucose | University of California, San Diego | Joseph Wang | Improving Lives | 01-October-2022 to 30-April-2027 | $867,998.91 |
| The Effects of Glucagon Antagonism on Insulin Resistance, Ketone Production, and Cardiovascular Risk in Individuals with Type 1 Diabetes | University of California, San Diego | Jeremy Pettus | Improving Lives | 01-June-2021 to 30-November-2026 | $1,233,752.52 |
| Acetazolamide and Tubuloglomerular Feedback in Persons with Type 1 Diabetes: A Clinical Trial | University of California, San Diego | Charles Ginsberg | Improving Lives | 01-November-2022 to 31-October-2026 | $1,356,726.45 |
| Deep Learning-based Analyses of Pancreatic Islet Beta-Cell Heterogeneity and MRI Pancreas Volume as Biomarkers to Improve Understanding of Type 1 Diabetes Progression | University of Florida | Sarah Kim | Cures | 01-June-2022 to 31-May-2026 | $744,090.11 |
| Evaluation of the safety, tolerability, and general response to Lactobacillus johnsonii N6.2 in children and adolescents with T1D | University of Florida | Graciela Lorca | Cures | 01-September-2019 to 31-August-2026 | $355,941.78 |